The group's principal activity is to develop targeted contrast agents to improve and expand the use of magnetic resonance imaging to diagnose human diseases. The group's principal product under development, ms-325, is an injectable intravascular contrast agent designed for multiple cardiovascular imaging applications, including peripheral vascular disease and coronary artery disease. Ms-325 is a small molecule chelate, which produces a mri signal. This molecule is designed with the group's proprietary technology to bind to albumin, the most common blood protein. Ms-325 is under human clinical trials.
